Boehringer Ingelheim posts Brightline-2 brigimadlin results; BI 4060107 trial recruits
Two Boehringer Ingelheim-linked registry records were last updated October 14, 2026, one with completed-trial results and one for a recruiting first-in-human study.
Two Boehringer Ingelheim-linked clinical trial registry records carry a last-update date of October 14, 2026.
- Brightline-2 (NCT05512377), a Phase IIa/IIb single-arm trial of brigimadlin (BI 907828) in patients with pancreatic neoplasms, solid tumors, biliary tract cancer, lung neoplasms, and bladder cancer1, is listed as completed, with results first posted October 14, 2026. The trial enrolled 99 participants1, and its primary outcome was objective response based on central independent review, defined as a confirmed complete or partial response per RECIST version 1.11.
- A first-in-human Phase I trial of BI 4060107 (NCT07827144), an open-label, multicentre study testing intravenous doses in adults with unresectable advanced or metastatic solid tumours2, is listed as recruiting, with Boehringer Ingelheim named as a collaborator under lead sponsor AIMEDBIO. The study began October 9, 2026, plans to enroll 90 participants2, and its primary outcome measures occurrence of dose limiting toxicities during the primary DLT evaluation period, assessed up to 21 days2.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.